Completed OBSERVATIONAL NCT02043145

Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Korea

Sponsor: Allergan

Conditions Glabellar Lines Hyperhidrosis Muscle Spasticity

Updated 10 times since 2017 Last updated: May 15, 2014 Started: Jul 31, 2008 Primary completion: Apr 30, 2012 Completion: Apr 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Glabellar Lines and Hyperhidrosis, this trial is completed. The trial is conducted by Allergan and has accumulated 10 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2023 — Jul 2024 [monthly]

Completed
Dec 2022 — Jan 2023 [monthly]

Completed

▶ Show 5 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Feb 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Jul 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allergan

Data source: Allergan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea